HARPOON THERAPEUTICS PRESENTS UPDATED INTERIM RESULTS AT ASH 2022 FOR NOVEL T CELL ENGAGER HPN217 IN RELAPSED/REFRACTORY MULTIPLE MYELOMA Clinically active across a wide dose range (2.15 to 24 mg) in a Phase 1 trial of heavily pretreated patients with...
Glympse to Present Data Demonstrating Sensitive Detection of Hepatocellular Carcinoma at AASLD The Liver Meeting 2022 -Data demonstrating novel platform to measure protease activity accurately differentiates patients with hepatocellular carcinoma (HCC) vs. patients...
Rallybio Announces Pricing of $50 Million Public Offering Rallybio Corporation (“Rallybio”) (Nasdaq: RLYB) today announced the pricing of an underwritten public offering of 5,000,001 shares of its common stock at a price to the public of $6.00 per share and, in lieu...
Cleerly Partners With Heartbeat Health for Increased Access to Early Cardiac Evaluations New alliance combines Cleerly’s AI-enabled approach to identifying early signs of heart disease with Heartbeat Health’s nationwide footprint of virtual cardiologists and care. New...
Cleerly’s Proxy solution improves heart disease imaging workflows Cleerly introduces Proxy solution to improve heart disease imaging workflowsProxy allows for seamless data transmission and improved AI-based plaque analysis Cleerly, the company creating a new...
BrightInsight Inks Enterprise Agreement with CSL Behring for Digital Health Solutions Across Brand Portfolio Following success of Hizentra App, CSL Behring and BrightInsight expand partnership to build apps for rare disease medicines across the globe BrightInsight,...
Recent Comments